Publications by authors named "Victor Abler"

19Publications

Evaluation of the efficacy of pimavanserin in the treatment of agitation and aggression in patients with Alzheimer's disease psychosis: A post hoc analysis.

Int J Geriatr Psychiatry 2020 Jul 30. Epub 2020 Jul 30.

ACADIA Pharmaceuticals Inc., San Diego, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/gps.5381DOI Listing
July 2020

Hospital utilization rates following antipsychotic dose reductions: implications for tardive dyskinesia.

BMC Psychiatry 2018 09 24;18(1):306. Epub 2018 Sep 24.

Teva Pharmaceutical Industries, 41 Moores Rd, Frazer, Malvern, PA, 19355, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12888-018-1889-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6154822PMC
September 2018

Abnormalities on structural MRI associate with faster disease progression in multiple system atrophy.

Parkinsonism Relat Disord 2019 01 7;58:23-27. Epub 2018 Aug 7.

Department of Neurology, Innsbruck Medical University, Innsbruck, Austria; Neuroimaging Core Facility, Innsbruck Medical University, Innsbruck, Austria.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S13538020183033
Publisher Site
http://dx.doi.org/10.1016/j.parkreldis.2018.08.004DOI Listing
January 2019

Physician perceptions of pharmacologic treatment options for chorea associated with Huntington disease in the United States.

Curr Med Res Opin 2018 04 16;34(4):643-648. Epub 2018 Feb 16.

d Vanderbilt University Medical Center , Nashville , TN , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/03007995.2018.1435518DOI Listing
April 2018

Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting.

Neurology 2018 01 13;90(2):74-82. Epub 2017 Dec 13.

From Muhammad Ali Parkinson Center (R.R.W.), Barrow Neurological Institute, Phoenix, AZ; Department of Neurology (F.K., G.K.W., W.P., K.S., N.S.), Medical University Innsbruck, Austria; National Institute of Neurological Disorders and Stroke (W.R.G., W.J.K.), NIH, Bethesda, MD; Department of Neurology (P.A.L.), Mayo Clinic, Rochester, MN; Brain and Mind Centre (G.H.), Sydney Medical School, the University of Sydney; UNSW Medicine & Neuroscience Research Australia (G.H.), Sydney; Queen Square Brain Bank (J.H.), UCL Institute of Neurology (N.P.Q.), London, UK; UPS, INSERM, and CHU de Toulouse (O.R.), University de Toulouse; Centre de Référence Maladie Rare contre l'AMS (O.R.), Centre d'Investigation Clinique CIC1436, Départments de Pharmacologie Clinique et de Neurosciences, NeuroToul/COEN Center of Excellence in Neurodegeneration, Toulouse, France; Department of Pathology & Laboratory Medicine (L.M.S.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Center for Neurosciences (D.E.), The Feinstein Institute for Medical Research, Manhasset, NY; The Multiple System Atrophy (MSA) Coalition, Inc. (P. B., J.B., P.F., L.K., C.L., C.R., S.S.), Charlotte, NC; Cleveland Clinic Lou Ruvo Center for Brain Health (J.L.C.), Las Vegas, NV; Medical Affairs (V.A.), Teva Pharmaceuticals, Frazer, PA; Department of Neurology (G.B.), David Geffen School of Medicine, Brain Research Institute, and Molecular Biology Institute, University of California at Los Angeles; Institute of Neurology (D.J.B.), University of Newcastle upon Tyne, UK; Van Andel Research Institute (P. Brundin), Center for Neurodegenerative Science, Grand Rapids, MI; Center for Neurological Restoration (H.F.), Cleveland Clinic, OH; Defeat MSA (P.F.); MSA Shoe Charity (P.F., C.R.), Saint Clair Shores, MI; Department of Neurology (R.F.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Neurodegenerative Diseases (T.G.), Hertie Institute of Clinical Brain Research, University of Tübingen; German Center for Neurodegenerative Diseases (DZNE) (T.G.), Tübingen, Germany; Lundbeck LLC (A.H.), Deerfield, IL; German Center for Neurodegenerative Diseases (DZNE) (G.U.H.), Munich; Department of Neurology (G.U.H.), Technical University of Munich, Germany; Neurogenomics Division (M.J.H.), The Translational Genomics Research Institute, Phoenix, AZ; Dandrite & Department of Biomedicine (P.H.J.), Aarhus University, Denmark; Quanterix (A.J.), Lexington, MA; Department of Neurology (U.J.K.), Columbia University Medical Center; Department of Neurology (H.K.), New York University School of Medicine, New York; Whitehead Institute for Biomedical Research (V.K.), Cambridge; Ann Romney Center for Neurologic Disease (V.K.), Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston; Harvard Stem Cell Institute (V.K.), Cambridge, MA; Department of Neurology (T.K.), University of Bonn; German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany; Brain and Mind Centre (W.S.K.), Sydney Medical School, University of Sydney, Australia; Department of Neurology (P.L.), Henry Ford Hospital; Department of Neurology (P.L.), Wayne State University School of Medicine, Detroit, MI; Division of Neurosciences (E.M.), National Institute on Aging/NIH, Bethesda, MD; Centre de Référence Maladie Rare AMS (W.M.), Hôpital Pellegrin, CHU de Bordeaux; Université de Bordeaux (W.M.), Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux; Paris Saclay Institute of Neuroscience (R.M.), CNRS, Gif-sur-Yvette, France; Genentech Inc. (S.O.), South San Francisco; Cedars-Sinai Medical Center (S.P.), Los Angeles, CA; Department of Neurology (D.R.), Vanderbilt University Medical Center, Nashville, TN; MSA NJ (C.R.), Howell, NJ; Prothena Biosciences (D.S.), South San Francisco, CA; Division of Neurology (M.S.), Department of Medicine, The Ottawa Hospital, Canada; Department of Neurology (J.D.S.), Massachusetts General Hospital, Harvard Medical School, Boston, MA; Cure MSA Foundation (L.S.), Fremont, CA; Avid Radiopharmaceuticals (A.S.), Philadelphia, PA; Department of Neurological Sciences (G.T.S.), Rush University Medical Center, Chicago, IL; Department of Neurology (S.T.), Graduate School of Medicine, Tokyo University, Tokyo, Japan; and University of Washington (J.Z.), Seattle. W.R.G. is currently affiliated with Janssen Research and Development, Titusville, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000004798DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5772155PMC
January 2018

Minimally clinically important decline in the parkinsonian variant of multiple system atrophy.

Mov Disord 2016 10;31(10):1577-1581

Department of Neurology, Medical University Innsbruck, Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.26743DOI Listing
October 2016

Long-term effects of rasagiline and the natural history of treated Parkinson's disease.

Mov Disord 2016 10;31(10):1489-1496

Departments of Neurology and Neuroscience, Mount Sinai School of Medicine, New York, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.26724DOI Listing
October 2016

Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson's disease: a pharmacogenetic study.

Brain 2016 07 13;139(Pt 7):2050-62. Epub 2016 May 13.

4 Neurogenetics Section, Centre for Addiction and Mental Health, Toronto, Canada 5 Institute of Medical Science, University of Toronto, Toronto, Canada 7 Department of Psychiatry, University of Toronto, Toronto, Canada 8 Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Canada 11 Biostatistics Division, Dalla Lana School of Public Health, University of Toronto, Toronto, Canada 12 Lancaster Medical School and Data Science Institute, Lancaster University, Lancaster, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/brain/aww109DOI Listing
July 2016

Efficacy of rasagiline in early Parkinson's disease: a meta-analysis of data from the TEMPO and ADAGIO studies.

Int J Neurosci 2016 Oct 18;126(10):942-6. Epub 2016 Mar 18.

c Teva Pharmaceuticals , Petah Tikva , Israel.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/00207454.2016.1154552DOI Listing
October 2016